{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-26-000022","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.017835+00:00","generated_at":"2026-05-14T21:59:57.607205+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Maravai LifeSciences Q1 revenue up 41% to $65.8M; raises full-year guidance","bullets":["Q1 2026 revenue $65.8M, up 40.5% YoY; net loss improved to $(6.4)M from $(52.9)M.","Adjusted EBITDA of $20.3M vs $(10.5)M prior year; generated $4.2M free cash flow.","TriLink revenue up 65.1% to $47.5M, driven by $14.3M COVID CleanCap orders; base TriLink up 15.4%.","Cygnus revenue $18.4M, up 1.4% due to strong North America/EMEA, offset by China timing.","Full-year 2026 revenue and Adjusted EBITDA guidance raised reflecting Q1 strength and improved visibility."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-26-000022","json":"https://secwatch.observer/filing/0001823239-26-000022.json","markdown":"https://secwatch.observer/filing/0001823239-26-000022.md","text":"https://secwatch.observer/filing/0001823239-26-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000022/0001823239-26-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000022/mrvi-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:59:57.607205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"968d1263201803a96c027c218de51cb52ef6d8f0","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported first quarter ended March 31, 2026 results: revenue $65.8 million, net income $(6.4) million. Guidance raised.","evidence_excerpt":"Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates. Key Financial Results: • Revenue of $65.8 million, Net loss of $(6.4) million, and Adjusted EBITDA of $20.3 million;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000022/0001823239-26-000022-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$65.8 million"},{"label":"Net income","value":"$(6.4) million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}